MedTrace Logo

Study of DNP002 in Patients With Solid Tumors

NCT06466265 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-06-20

No results posted yet for this study

Summary

This is an open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of the anti-Carcinoembryonic-antigen-related-cell-adhesion-molecule-6 (CEACAM6) antibody DNP002 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

DNP002

Anti-CEACAM6 monoclonal antibody

Sponsors & Collaborators

  • Kumho HT Inc.

    lead INDUSTRY

Principal Investigators

  • Moonki Choi, M.D., Ph.D. · National Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-24
Primary Completion
2024-12-31
Completion
2025-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06466265 on ClinicalTrials.gov